drug · oligonucleotide
olezarsen sodium
Marketedupdated 3mo agoby $IONS IONIS PHARMACEUTICALS INC🔗 ChEMBL
Approvedcommunity read0 votes
Oligonucleotide drug with a maximum clinical stage of Unknown (across all indications), with 2 investigational indications.
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 19, 2031
~5.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- May 1, 2034method-of-use (U-4050)US 12509684
- May 1, 2034compositionUS 9127276
- May 1, 2034compositionUS 9163239
- May 1, 2034compositionUS 9181549
- Feb 14, 2034method-of-use (U-4050)US 9593333
- Apr 27, 2032method-of-use (U-4050)US 9157082
FDA exclusivities (1)
- Dec 19, 2031ODE-515Orphan Drug (7y)
News(5)
- BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotechBioNTech’s leadership transition was announced earlier this year, with CEO Ugur Sahin and CMO Özlem Türeci leaving to start a new mRNA company. Guido Oelkers of Swedish Orphan Biovitrum AB will tak…biospace · 8d ago
- Biotechs bring big launches and pharma rivalries into Q2 earnings periodWith the second quarter earnings period underway, BioSpace examines five biotechs with meaningful catalysts that analysts and investors are watching.biospace · 14d ago
- FDA panel confronting peptide controversyToday's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."stat · 19d ago
- Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drugTo analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.biopharma_dive · 20d ago
- Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drugWith Phase 3 data showing what analysts called a “potentially best-in-class profile,” Arrowhead Pharmaceuticals plans to submit for FDA approval of plozasiran by the end of the year—hoping to follo…biospace · 20d ago
Data sources
last refreshed 21m ago
Found something off?
comments(0)
5-min edit window · permanent after that